Remi Bader Compared to Other Public GLP-1 Figures

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for Remi Bader Compared to Other Public GLP-1 Figures

At a glance

  • Celebrity: Remi Bader, plus-size influencer and model
  • Drug: Ozempic (semaglutide 0.5 to 1 mg, off-label for weight management)
  • Status: Confirmed use, confirmed discontinuation, confirmed weight regain
  • Clinical parallel: STEP 1 extension data on post-cessation weight rebound
  • Subsequent intervention: Bariatric surgery (publicly disclosed)

Remi Bader's Public GLP-1 Timeline

Remi Bader built her platform as a plus-size fashion influencer known for realistic try-on hauls. In interviews and social media posts, she confirmed that she had used Ozempic, the branded form of semaglutide approved for type 2 diabetes but widely prescribed off-label for weight loss. She did not disclose the exact duration of use or her prescribed dose.

What made Bader's account unusual was what came next. She publicly described significant weight regain after stopping the medication, stating that she gained back more weight than she had originally lost. This disclosure stood in sharp contrast to the silence that surrounds discontinuation among most public GLP-1 users. Bader later confirmed she pursued bariatric surgery, framing it as a decision made after the rebound experience with Ozempic proved unsustainable.

Her timeline, from GLP-1 initiation to discontinuation to surgical intervention, is the most completely documented celebrity arc in this drug class to date.

The Discontinuation Problem: What Clinical Data Shows

Bader's rebound experience is not an outlier. The STEP 1 trial extension study, published in Diabetes, Obesity and Metabolism in 2022, followed participants for one year after they stopped weekly semaglutide 2.4 mg. The findings were striking: participants regained approximately two-thirds of the weight they had lost during the 68-week treatment period. Cardiometabolic improvements in blood pressure, lipid levels, and HbA1c also reversed.

This pattern reflects the biology of GLP-1 receptor agonists. Semaglutide works by mimicking the incretin hormone GLP-1, reducing appetite through hypothalamic signaling, slowing gastric emptying, and improving insulin sensitivity. These effects persist only while the drug is active. Once discontinued, the physiological drivers of appetite and energy storage return to baseline, and in some patients, compensatory hunger may exceed pre-treatment levels.

The HealthRX Medical Team notes that Bader's description of regaining more than she lost is consistent with a phenomenon observed in weight cycling research. Repeated cycles of loss and regain can shift body composition toward higher fat mass and lower lean mass, a pattern sometimes called "fat overshooting" in the metabolic literature.

How Other Celebrities Have Discussed GLP-1 Use

To understand what makes Bader's disclosure distinctive, it helps to examine how other public figures have addressed their GLP-1 use. The differences in transparency, timing, and framing are significant.

Confirmed users:

  • Oprah Winfrey confirmed GLP-1 medication use in a December 2023 interview with People magazine, though she did not initially specify the drug. She later disclosed she was using a GLP-1 receptor agonist as part of a medically supervised program. Winfrey framed the medication as a tool she wished she had accessed sooner, and she has continued to discuss ongoing use rather than discontinuation.

  • Tracy Morgan confirmed Ozempic use in public interviews, noting weight loss as a motivator. His disclosure was brief, without detailed discussion of side effects or long-term plans.

  • Charles Barkley publicly confirmed semaglutide use, discussing visible weight loss and framing it positively. Like most confirmed users, he has spoken primarily about initiation and results, not about what happens if the drug is stopped.

Speculated but not confirmed:

Several other celebrities have been publicly speculated to use GLP-1 medications based on visible physical changes, but these individuals have either denied use or declined to comment. The HealthRX Medical Team does not treat speculation as evidence. Physical changes alone cannot confirm GLP-1 use, as weight loss has many possible causes including dietary modification, exercise, other medications, or surgical intervention.

The disclosure gap:

The pattern across these cases is consistent. Celebrities who confirm GLP-1 use tend to discuss the "starting" phase: the decision, early results, and positive framing. Almost none discuss discontinuation planning, rebound risk, or what happens when the prescription ends. Bader is a rare exception. Her willingness to describe the full cycle, from start through cessation to regain, provides a public data point that most celebrity disclosures deliberately omit.

Why Discontinuation Rebound Is a Clinical Concern, Not a Personal Failure

The HealthRX Medical Team emphasizes that weight regain after GLP-1 discontinuation is a predicted pharmacological outcome, not a failure of willpower. The American Gastroenterological Association's 2024 clinical practice update explicitly addresses this: obesity is a chronic disease requiring ongoing treatment, and stopping anti-obesity medication should be expected to produce weight regain in most patients, just as stopping antihypertensive medication produces blood pressure increases.

Current FDA-approved semaglutide labeling for the Wegovy formulation (2.4 mg weekly) does not specify a recommended treatment duration. The clinical expectation is indefinite use for sustained benefit. This creates a practical tension: many patients, including those prescribed off-label Ozempic at lower doses (0.5 to 1 mg), face insurance denials, cost barriers exceeding $1,000 per month without coverage, or personal decisions to stop, all of which lead to the rebound cycle Bader described publicly.

Semaglutide's half-life of approximately one week means physiological effects taper gradually over four to five weeks after the last injection. Appetite typically returns within this window. Patients who have lost significant weight on the medication may experience a metabolic adaptation: their resting energy expenditure is lower than predicted for their new body weight, a phenomenon well-documented in weight loss research and sometimes called adaptive thermogenesis. This creates a biological environment where regain is not merely possible but probable.

The Bariatric Surgery Decision After GLP-1 Failure

Bader's subsequent choice to pursue bariatric surgery reflects a clinical pathway that obesity medicine specialists increasingly recognize. For patients who experience GLP-1 rebound and cannot maintain pharmacotherapy long-term, surgical options, particularly sleeve gastrectomy and Roux-en-Y gastric bypass, offer durable weight reduction through permanent anatomical changes that alter gut hormone signaling.

Bariatric surgery produces its own sustained increase in endogenous GLP-1 secretion, along with changes in ghrelin, PYY, and bile acid metabolism. In effect, the surgery creates a version of the hormonal environment that exogenous semaglutide provides temporarily. Five-year data from randomized controlled trials show that bariatric surgery maintains 20 to 30% total body weight loss, compared to the 10 to 15% typically seen with GLP-1 agonists during active treatment.

The HealthRX Medical Team considers Bader's trajectory (GLP-1 trial, discontinuation, rebound, then surgery) a sequence that will become more common as the first wave of GLP-1 prescriptions encounters real-world adherence and cost barriers. This pattern warrants honest clinical conversation at the point of prescribing, not after rebound has already occurred.

What the Celebrity Disclosure Record Teaches Clinicians

The collection of public GLP-1 disclosures, taken together, reveals something useful for clinical practice. When high-profile individuals discuss only the positive initiation phase, it reinforces a public perception that these medications are a simple, permanent fix. When someone like Bader discloses the full arc, it aligns public understanding with clinical reality.

Prescribers should note three practical takeaways from the celebrity disclosure record:

  1. Patients arrive with expectations shaped by incomplete narratives. A patient who has seen multiple celebrities discuss dramatic GLP-1 results may not understand that those results require ongoing treatment. The informed consent conversation should explicitly address discontinuation rebound, citing STEP 1 extension data.

  2. Discontinuation is not always voluntary. Cost, insurance changes, supply shortages, and side effect burden all drive cessation. Clinicians should develop tapering and transition protocols rather than treating abrupt stops as the default.

  3. Rebound weight gain is a medical event, not a character flaw. The framing matters. Patients who internalize regain as personal failure are less likely to re-engage with evidence-based treatment. Bader's public framing of her experience as a medical reality, not a personal shortcoming, is clinically constructive.

Frequently asked questions

›
›
›
›
›

References

  • Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
  • Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide." Diabetes Obes Metab. 2022. https://pubmed.ncbi.nlm.nih.gov/35441470/
  • Müller TD, et al. "Glucagon-like peptide 1 (GLP-1)." Mol Metab. 2019. https://pubmed.ncbi.nlm.nih.gov/31563981/
  • Dulloo AG, et al. "How dieting makes the lean fatter." Obes Rev. 2015. https://pubmed.ncbi.nlm.nih.gov/25614201/
  • Rosenstock J, et al. "Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin." JAMA. 2019. https://pubmed.ncbi.nlm.nih.gov/28653857/
  • Rosenbaum M, Leibel RL. "Adaptive thermogenesis in humans." Int J Obes. 2010. https://pubmed.ncbi.nlm.nih.gov/23404923/
  • Schauer PR, et al. "Bariatric Surgery versus Intensive Medical Therapy for Diabetes, 5-Year Outcomes." N Engl J Med. 2017. https://pubmed.ncbi.nlm.nih.gov/28402290/
  • Arterburn DE, et al. "Benefits and Risks of Bariatric Surgery in Adults." JAMA. 2020. https://pubmed.ncbi.nlm.nih.gov/28616630/
  • Garvey WT, et al. "AGA Clinical Practice Update on the Role of GLP-1 Receptor Agonists." Gastroenterology. 2024. https://pubmed.ncbi.nlm.nih.gov/37890571/
  • FDA Wegovy Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_cps/approve.cfm